Gut microbiome in chronic kidney disease
Abass, N. (2018). Gut microbiome in chronic kidney disease. EKB Journal Management System, 22(1), 415-420. doi: 10.21608/smj.2018.42518
Noher Mohammad Abass. "Gut microbiome in chronic kidney disease". EKB Journal Management System, 22, 1, 2018, 415-420. doi: 10.21608/smj.2018.42518
Abass, N. (2018). 'Gut microbiome in chronic kidney disease', EKB Journal Management System, 22(1), pp. 415-420. doi: 10.21608/smj.2018.42518
Abass, N. Gut microbiome in chronic kidney disease. EKB Journal Management System, 2018; 22(1): 415-420. doi: 10.21608/smj.2018.42518

Gut microbiome in chronic kidney disease

Sohag Medical Journal
Article 57, Volume 22, Issue 1, January 2018, Page 415-420  XML PDF (68.42 K)
Document Type: Original Article
DOI: 10.21608/smj.2018.42518
View on SCiNiTO View on SCiNiTO
Author
Noher Mohammad Abass
Department of Internal Medicine, Sohag Faculty of Medicine, Sohag University.
Supplementary Files
References
  1. Bäckhed F, Ley RE, Sonnenburg JL,Peterson DA, Gordon JI: Host-bacterial utualism in the human intestine. Science 2005; 307: 1915–1920.
  2. Ley RE, Turnbaugh PJ, Klein S, Gordon JI: Microbial ecology: Human gut microbes associated with obesity. Nature 2006; 444: 1022–1023.
  3. Qin J, Li Y, Cai Z, Li S, Zhu J, Zhang F, Liang S, ZhangW, Guan Y: Ametagenome-wide association study of gut microbiota in type 2 diabetes. Nature  2012; 490: 55–60.
  4. Frank DN, St Amand AL, Feldman RA, Boedeker EC, Harpaz N, Pace NR: Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc Natl Acad Sci US A 2007; 104: 13780–13785.
  5. Wang Z, Klipfell E, Bennett BJ, Koeth R, Levison BS, Dugar B, Feldstein AE, Britt EB, Fu X, Chung YM,WuY, Schauer P, Smith JD, Allayee H, TangWH, Di Donato JA, Lusis AJ, Hazen SL: Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature 2011; 472: 57–63
  6. Vaziri ND,Wong J, Pahl M, Piceno YM, Yuan J, De Santis TZ, Ni Z, Nguyen TH, Andersen GL: Chronic kidney disease alters intestinal microbial flora. Kidney Int  2013; 83: 308–315.
  7. De Felippo C, Cavalieri D, Di Paola M, Ramazzotti M, Poullet JB, Massart S, Collini S, Pieraccini G & Lionetti P : Impact of diet in shaping gut microbiota revealed by a comparative study in children from Europe and rural Africa. Proc Natl Acad Sci USA 2010; 107, 14691–14696.
  8. Dethlefsen L & Relman DA : Incomplete recovery and individualized responses of the human distal gut microbiota to repeated antibiotic perturbation. Proc Natl Acad Sci USA  2011; 108 Suppl 1 , 4554–4561.
  9. Goodrich JK,Waters JL, Poole AC, Sutter JL, Koren O, Blekhman R, Beaumont M, Van Treuren W, Knight R, Bell JT, Spector TD, Clark AG & Ley RE : Human genetics shape the gut microbiome. Cell 2014; 159, 789–799.
  10. Amar J, Lange C, Payros G, Garret C, Chabo C, Lantieri O, Courtney M, Marre M, harles MA, Balkau B & Burcelin R : Blood microbiota dysbiosis is associated with the onset of cardiovascular events in a large general population: the D.E.S.I.R. study. PLoS One 2013; 8: e54461.
  11. De Angelis M, Montemurno E, Piccolo M, Vannini L, Lauriero G, Maranzano V, Gozzi G, Serrazanetti D, Dalfino G, Gobbetti M & Gesualdo L :Microbiota and metabolome associated with immunoglobulin A nephropathy (IgAN). PLoS One 2014;9: e99006.
  12. Zheng X, Zhao A, Xie G, Chi Y, Zhao L, Li H,Wang C, Bao Y, JiaW, Luther M, Su , Nicholson JK & JiaW: Melamine-induced renal toxicity is mediated by the gut microbiota. Sci Transl Med  2013;5: 172- 22.
  13. Andrade-Oliveira V, Amano MT, Correa-Costa M, Castoldi A, Felizardo RJ, de Almeida DC, Bassi EJ, Moraes-Vieira PM, Hiyane MI, Rodas AC, Peron JP, Aguiar CF, Reis MA, Ribeiro WR, Valduga CJ, Curi R, Vinolo MA, Ferreira CM& Cˆamara NO : Gut bacteria products prevent AKI induced by ischemia–reperfusion. J Am Soc Nephrol 2015;26: 1877–1888.
  14. Vaziri ND,Wong J, Pahl M, Piceno YM, Yuan J, Desantis TZ: Chronic kidney disease alters intestinal microbial flora. Kidney Int.2013; 83(2):308–15.
  15. Hida M, Aiba Y, Sawamura S, Suzuki N, Satoh T: Inhibition of the accumulation of uremic toxins in the blood and their precursors in the feces after oral administration of Lebenin, a lactic acid bacteria preparation, to uremic patients undergoing hemodialysis. Nephron. 1996;74(2):349–55.
  16. Schepers E, Glorieux G, Vanholder R: The gut: the forgotten organ in uremia? Blood Purif. 2010;29(2):130–6.
  17. Ramezani A & Raj DS : The gut microbiome, kidney disease, and targeted interventions. J Am Soc Nephrol 2014; 25: 657–670.
  18. Wu MJ, Chang CS, Cheng CH, Chen CH, LeeWC, Hsu YH, Shu KH & Tang MJ : Colonic transit time in long-term dialysis patients. Am J Kidney Dis 2004; 44: 322–327.
  19. Alderman MH, Cohen H, Madhavan S & Kivlighn S : Serum uric acid and cardiovascular events in successfullytreated hypertensive patients. Hypertension 1999; 34:144–150.
  20. Wong J, Piceno YM, DeSantis TZ, Pahl M, Andersen GL & Vaziri ND : Expansion of urease- and uricase-containing, indole- and p-cresol-forming and contraction of short-chain fatty acid-producing intestinal microbiota in ESRD. Am J Nephrol  2014;39: 230–237.
  21. Ramezani A,Massy ZA, Meijers B, Evenepoel P, Vanholder R, Raj DS: Role of the gut microbiome in uremia: a potential therapeutic target. Am J Kidney Dis. 2016; 67(3):483–98.
  22. Carrero JJ, Stenvinkel P: Inflammation in end-stage renal disease- what have we learned in 10 years? Semin Dial. 2010; 23(5):498–509.
  23. Koren O, Spor A, Felin J, Fak F, Stombaugh J, Tremaroli V:Human oral, gut, and plaque microbiota in patients with atherosclerosis. Proc Natl Acad Sci U S A. 2011;108(Suppl 1):4592–8.
  24. Wiedermann CJ, Kiechl S, Dunzendorfer S, Schratzberger P, EggerG, Oberhollenzer F: Association of endotoxemia with carotid atherosclerosis and cardiovascular disease: prospective results from the Bruneck Study. J Am Coll Cardiol. 1999; 34(7):1975–81.
  25. Poesen Rl, Ramezani A, Claes K, Augustijns P, Kuypers D, Barrows : Associations of soluble CD14 and endotoxin with mortality, cardiovascular disease, and progression of kidney disease among patients with chronic kidney disease. CJASN. 2015; In Press.
  26. Lin CJ,Wu V,Wu PC,Wu CJ : Meta-analysis of the associations of p-cresyl sulfate (PCS) and indoxyl sulfate (IS) with cardiovascular events and all-cause mortality in patients with chronic renal failure . PLoS One. 2015;10(7):e0132589.
  27. Velasquez MT, Ramezani A, Manal A, Raj DS:Trimethylamine NOxide:The Good, the Bad and the Unknown. Toxins (Basel). 2016; 8(11).
  28. Tang WH, Wang Z, Kennedy DJ, Wu Y, Buffa JA, Agatisa-Boyle B: Gut microbiota-dependent trimethylamine N-oxide (TMAO) pathway contributes to both development of renal insufficiency and mortality risk in chronic kidney disease. Circ Res. 2015;116(3):448–55.
  29. Tang WH, Wang Z, Fan Y, Levison B, Hazen JE, Donahue LM: Prognostic value of elevated levels of intestinal microbegenerated metabolite trimethylamine-N-oxide in patients with heart failure: refining the gut hypothesis. J Am Coll Cardiol. 2014; 64(18):1908–14.
  30. Yang T, Santisteban MM, Rodriguez V, Li E, Ahmari N, Carvajal JM: Gut dysbiosis is linked to hypertension. Hypertension. 2015; 65(6):1331–40.
  31. Macfarlane S, Macfarlane GT: Regulation of short-chain fatty acid production. Proc Nutr Soc. 2003; 62(1):67–72.
  32. Le PE, Loison C, Struyf S, Springael JY, annoy V, DecobecqME: Functional characterization of human receptors for short chain fatty acids and their role in polymorphonuclear cell activation. J Biol Chem. 2003; 278(28):25481–9.
  33. Round JL, Mazmanian SK:The gut microbiota shapes intestinal immune responses during health and disease. Nat Rev Immunol. 2009; 9(5):313–23.
  34. Mortensen FV, Nielsen H,MulvanyMJ, Hessov I: Short chain fatty acids dilate isolated human colonic resistance arteries. Gut. 1990; 31(12):1391–4.
  35. Pluznick JL, Zou DJ, Zhang X, Yan Q, Rodriguez-Gil DJ, Eisner C et al: Functional expression of the olfactory signaling system in the kidney. Proc Natl Acad Sci U S A 2009; 106(6):2059–2064.
  36. Gibson GR, Probert HM, Loo JV, Rastall RA, Roberfroid MB: Dietary  modulation of the human colonic microbiota: Updating the concept of prebiotics. Nutr Res Rev 2004; 17: 259–275.
  37. Silk DB, Davis A, Vulevic J, Tzortzis G, Gibson GR: Clinical trial: the effects of a trans-galactooligosaccharide prebiotic on faecal microbiota and symptoms in irritabl bowel syndrome. Aliment Pharmacol Ther 2009; 29: 508–518.
  38. Cani PD, Neyrinck AM, Fava F, Knauf C, Burcelin RG, Tuohy KM,GibsonGR, elzenne NM: Selective increases of bifidobacteria in gut microflora improve high-fat-diet-induced diabetes in mice through a mechanism associated with endotoxaemia. Diabetologia  2007; 50: 2374–2383.
  39. Krishnamurthy VM, WeiG, Baird BC,Murtaugh M, Chonchol MB, Raphael KL, Greene T, Beddhu S: High dietary fiber intake is associated with decreased inflammation and all cause mortality in patients with chronic kidney disease. Kidney Int 2012; 81: 300–306.
  40. Food and Agriculture Organization of the United Nations (FAO). Health and nutritional properties of probiotics in food including powder milk with live lactic acid bacteria. Available at: Accessed October 30, 2013.
  41. van Baarlen P, Troost FJ, van Hemert S, vander Meer C, de Vos WM, de Groot PJ, Hooiveld GJ, Brummer RJ, Kleerebezem M; van BP: Differential NF-kappaB pathways induction by Lactobacillus plantarum in the duodenum of healthy humans correlating with immune tolerance. Proc Natl Acad Sci U S A 2009; 106: 2371–2376.
  42. Evenepoel P, Bammens B, Verbeke K,Vanrenterghem Y: Acarbose treatmentlowers generation and serum concentrations of the protein-bound solute p-cresol: a pilot study. Kidney Int 2006; 70: 192–198.
  43. Persky SE, Brandt LJ: Treatment of recurrent Clostridium difficile-associated diarrhea by administration of donated stool directly through a colonoscope. Am J Gastroenterol 2000; 95: 3283–3285.
Statistics
Article View: 205
PDF Download: 341